PDXDC2 Inhibitors
PDXDC2 inhibitors are a class of chemical compounds designed to selectively inhibit the enzyme pyridoxal-dependent decarboxylase 2 (PDXDC2), which plays a significant role in vitamin B6 metabolism. PDXDC2 is responsible for the decarboxylation of 4-pyridoxic acid to produce 4-pyridoxyl phosphate, a reaction that contributes to the overall utilization of vitamin B6 in various biochemical pathways. The regulation of this enzyme is crucial as it influences the availability of vitamin B6 in its active form, pyridoxal 5'-phosphate (PLP), which acts as a cofactor for numerous enzymatic reactions in amino acid metabolism, neurotransmitter synthesis, and more. Inhibition of PDXDC2 can lead to a decrease in the production of PLP and subsequently affect various metabolic processes.
The discovery and characterization of PDXDC2 inhibitors involve multiple approaches, including structure-based drug design and high-throughput screening of compound libraries. Understanding the enzyme's three-dimensional structure provides insights into its active site and binding pockets, enabling the design of small molecules that can effectively inhibit its activity. Through structure-activity relationship (SAR) studies, researchers can modify lead compounds to enhance their binding affinity and specificity towards PDXDC2. Investigating the biochemical pathways influenced by PDXDC2 and its inhibitors further elucidates the intricate role of vitamin B6 metabolism in cellular functions. By studying PDXDC2 inhibitors, scientists gain valuable information about the regulatory mechanisms of vitamin B6 and its derivatives, as well as the broader implications of these pathways in metabolic homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gabaculine | 59556-17-1 | sc-200473 sc-200473A sc-200473B | 10 mg 50 mg 250 mg | $354.00 $884.00 $3069.00 | 5 | |
Gabaculine acts as an irreversible inhibitor of GABA transaminase, affecting the metabolism of neurotransmitters and amino acids. By inhibiting GABA transaminase, gabaculine alters the balance of pyridoxal phosphate, a cofactor likely essential for PDXDC2 function, thus impeding PDXDC2 activity. | ||||||
Vigabatrin | 60643-86-9 | sc-204382 sc-204382A sc-204382B sc-204382C | 10 mg 50 mg 100 mg 1 g | $125.00 $485.00 $650.00 $1015.00 | 2 | |
Vigabatrin selectively inhibits GABA transaminase, increasing GABA levels and thereby modifying the availability of pyridoxal phosphate. This alteration in cofactor dynamics can inhibit PDXDC2 activity by limiting the cofactor's availability. | ||||||
Phenethyl-hydrazine | 51-71-8 | sc-331686 | 500 mg | $396.00 | ||
Phenelzine, a monoamine oxidase inhibitor, influences amine metabolism and can impact the availability of pyridoxal phosphate. This influence extends to PDXDC2, where altered cofactor levels can impede enzyme activity. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine chelates pyridoxal phosphate, reducing its availability for enzymes like PDXDC2, which may depend on this cofactor for activity. | ||||||
Isoniazid | 54-85-3 | sc-205722 sc-205722A sc-205722B | 5 g 50 g 100 g | $26.00 $101.00 $146.00 | ||
Isoniazid binds to pyridoxal phosphate and forms a hydrazone complex, decreasing the bioavailability of the cofactor for pyridoxal phosphate-dependent enzymes such as PDXDC2, inhibiting its function. | ||||||
D-Cycloserine | 68-41-7 | sc-221470 sc-221470A sc-221470B sc-221470C | 200 mg 1 g 5 g 25 g | $28.00 $77.00 $142.00 $530.00 | 4 | |
Cycloserine is an antibiotic that inhibits alanine racemase and D-alanine:D-alanine ligase, enzymes involved in amino acid metabolism. This inhibition can lead to changes in the cellular levels of amino acids, thereby affecting PDXDC2 activity. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline is a phosphodiesterase inhibitor that can alter intracellular cAMP levels, influencing gene expression and enzymatic activity, including that of PDXDC2. | ||||||
Levodopa | 59-92-7 | sc-205372 sc-205372A | 5 g 25 g | $54.00 $171.00 | 9 | |
Levodopa is a precursor to dopamine and can lead to feedback inhibition of decarboxylases. By saturating the enzyme with substrate, levodopa can inhibit PDXDC2 function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG interacts with various proteins and enzymes, potentially altering their function. By binding to or interfering with the active site or cofactor-binding regions, EGCG can inhibit PDXDC2 activity. | ||||||
L-Ascorbic acid, free acid | 50-81-7 | sc-202686 | 100 g | $46.00 | 5 | |
Ascorbic acid engages in redox reactions and can modulate gene expression and enzyme activity. This modulation can influence the activity of PDXDC2 by altering the enzyme's redox state or gene regulation. | ||||||